CymaBay Therapeutics Inc (NASDAQ:CBAY) – Research analysts at Oppenheimer decreased their FY2021 earnings per share (EPS) estimates for shares of CymaBay Therapeutics in a note issued to investors on Tuesday, June 11th. Oppenheimer analyst J. Olson now anticipates that the biopharmaceutical company will earn ($1.31) per share for the year, down from their previous forecast of ($1.07). Oppenheimer has a “Buy” rating and a $12.00 price objective on the stock. Oppenheimer also issued estimates for CymaBay Therapeutics’ FY2022 earnings at ($0.29) EPS and FY2023 earnings at $0.55 EPS.
Other equities research analysts also recently issued research reports about the stock. Svb Leerink reiterated an “outperform” rating on shares of CymaBay Therapeutics in a research note on Thursday, February 21st. Zacks Investment Research downgraded shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 14th. ValuEngine downgraded shares of CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 7th. Citigroup decreased their target price on shares of CymaBay Therapeutics from $21.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday. Finally, BidaskClub upgraded shares of CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, April 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $14.44.
Shares of CBAY opened at $6.28 on Friday. CymaBay Therapeutics has a fifty-two week low of $4.82 and a fifty-two week high of $15.00. The stock has a market cap of $463.66 million, a PE ratio of -4.98 and a beta of 1.73. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.66 and a quick ratio of 18.66.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03).
A number of large investors have recently made changes to their positions in CBAY. Bank of New York Mellon Corp lifted its position in CymaBay Therapeutics by 6.9% in the third quarter. Bank of New York Mellon Corp now owns 259,311 shares of the biopharmaceutical company’s stock valued at $2,873,000 after purchasing an additional 16,804 shares during the period. Vanguard Group Inc. lifted its position in CymaBay Therapeutics by 4.1% in the third quarter. Vanguard Group Inc. now owns 2,789,188 shares of the biopharmaceutical company’s stock valued at $30,903,000 after purchasing an additional 109,989 shares during the period. Rhumbline Advisers lifted its position in CymaBay Therapeutics by 47.4% in the fourth quarter. Rhumbline Advisers now owns 77,946 shares of the biopharmaceutical company’s stock valued at $613,000 after purchasing an additional 25,057 shares during the period. PNC Financial Services Group Inc. lifted its position in CymaBay Therapeutics by 23.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 2,460 shares during the period. Finally, Pearl River Capital LLC acquired a new stake in CymaBay Therapeutics in the fourth quarter valued at about $74,000. Hedge funds and other institutional investors own 99.53% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Read More: Why does the United States have a lingering trade deficit?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.